This trial which is so far the largest to be conducted on the continent to identify early COVID-19 treatments that can prevent progression to severe disease and potentially limit transmission has established sites at Makerere and Kabale universities in Uganda.
Kaleebu who was commenting on the deliberations at the meeting told URN that already UVRI is in early stages of working on a Messenger RNA vaccine but their biggest challenge like elsewhere is having to rely on foreign funding.
A large proportion of information shared on online media platforms since the pandemic started global agencies say is inaccurate and misleading and continues to be shared by social media users intentionally or unknowingly every day.
The study dubbed ANTIVOC is launching at 19 sites across 13 countries where 2000 to 3000 patients with mild infection will be enrolled on various treatments to test their safety and efficacy in preventing the disease from progressing into severe state. The countries involved are Burkina Faso, Cameroon, Côte d’Ivoire, the Democratic Republic of Congo (DRC), Equatorial Guinea, Ethiopia, Ghana, Guinea, Kenya, Mali, Mozambique, Sudan, and Uganda.